Authors:
Hidalgo, M
Aylesworth, C
Hammond, LA
Britten, CD
Weiss, G
Stephenson, J
Schwartz, G
Patnaik, A
Smith, L
Molpus, K
Felton, S
Gupta, E
Ferrante, KJ
Tortora, A
Sonnichsen, DS
Skillings, J
Rowinsky, EK
Citation: M. Hidalgo et al., Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel, J CL ONCOL, 19(9), 2001, pp. 2493-2503
Authors:
Tolcher, AW
Eckhardt, SG
Kuhn, J
Hammond, L
Weiss, G
Rizzo, J
Aylesworth, C
Hidalgo, M
Patnaik, A
Schwartz, G
Felton, S
Campbell, E
Rowinsky, EK
Citation: Aw. Tolcher et al., Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties, J CL ONCOL, 19(11), 2001, pp. 2937-2947
Authors:
Tolcher, AW
Aylesworth, C
Rizzo, J
Izbicka, E
Campbell, E
Kuhn, J
Weiss, G
Von Hoff, DD
Rowinsky, EK
Citation: Aw. Tolcher et al., A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenousinfusion in patients with advanced solid tumors, ANN ONCOL, 11(3), 2000, pp. 333-338
Authors:
Rowinsky, EK
Humphrey, R
Hammond, LA
Aylesworth, C
Smetzer, L
Hidalgo, M
Morrow, M
Smith, L
Garner, A
Sorensen, JM
Von Hoff, DD
Eckhardt, SG
Citation: Ek. Rowinsky et al., Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patientswith solid malignancies, J CL ONCOL, 18(1), 2000, pp. 178-186
Authors:
Petit, T
Aylesworth, C
Burris, H
Ravdin, P
Rodriguez, G
Smith, L
Peacock, N
Smetzer, L
Bellet, R
Von Hoff, DD
Rowinsky, EK
Citation: T. Petit et al., A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies, ANN ONCOL, 10(2), 1999, pp. 223-229